Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes

• Status: Completed
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the effectiveness of ziprasidone treatment versus treatment with a standard atypical antipsychotic drug in improving insulin sensitivity and reducing excess abdominal fat storage in people with schizophrenia who are at risk for diabetes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Veterans Medical Research Foundation
• Collaborators: National Institute of Mental Health (NIMH); Pfizer
• Treatments: Antipsychotic Agents; Insulin; Olanzapine; Risperidone; Ziprasidone

Criteria

Inclusion Criteria:

• Diagnosis of schizophrenia or schizoaffective disorder

• Currently receiving antipsychotic therapy with risperidone or olanzapine

• Overweight

Exclusion Criteria:

• Diagnosis of diabetes

• Hospitalization for schizophrenia or schizoaffective disorder within 90 days prior to study entry

• Refractory schizophrenia or schizoaffective disorder

• Currently receiving therapy with clozapine

• No stable residence and phone number for 90 days prior to study entry

• Prior unsuccessful treatment with ziprasidone

• Intolerance to ziprasidone